Please login to the form below

Not currently logged in
Email:
Password:

managed access programmes

This page shows the latest managed access programmes news and features for those working in and with pharma, biotech and healthcare.

Clinigen acquires Idis for £225m

Clinigen acquires Idis for £225m

Idis supplies unlicensed medicines predominantly on an exclusive basis through managed access programmes as well as on demand via its general access division.

Latest news

  • Langland triumphs at IPA Best of Health Awards Langland triumphs at IPA Best of Health Awards

    In addition to picking up Best of Show, Langland's campaign for Idis – which develops managed access programmes – also won Best use of Art Direction and a Gold Award for Healthcare

  • Langland leads Global Award winners Langland leads Global Award winners

    I did this with Idis', an international campaign, was built around a series of documentary films designed to raise awareness of Idis' managed access programmes.

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Former Quintiles president Jeff Thomis to chair Idis Former Quintiles president Jeff Thomis to chair Idis

    Former Quintiles president Jeff Thomis to chair Idis. Will oversee company’ s activities to develop managed access programmes for medicines. ... Idis has appointed Jeff Thomis as chairman to oversee the company's activities in creating managed access

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics